18F FDG PET/CT and head and neck cancer: Patient management and outcomes

Sara Sheikhbahaei, Charles Marcus, Rathan M. Subramaniam

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


There is a growing body of evidence that point to the value of 18F fluoro-deoxyglucose-PET/CT in the management of head and neck cancer (HNC) patients and predicting patient-related outcomes. FDG-PET/CT changes the baseline staging (compared with CT or MR imaging), guides appropriate therapy selection, separates the responders and non-responders for therapy assessment, adds value to clinical assessment in follow-up, and predicts patient survival outcomes. FDG-PET/CT can identify the recurrences in earlier stages and individualize follow-up regimens in HNC patients. This article reviews the value of FDG-PET/CT in management strategy and survival outcome of HNC patients.

Original languageEnglish (US)
Pages (from-to)125-145
Number of pages21
JournalPET Clinics
Issue number2
StatePublished - Apr 1 2015


  • Head and neck squamous cell cancer
  • Management change
  • Prognosis
  • Survival outcome
  • Therapy response

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of '18F FDG PET/CT and head and neck cancer: Patient management and outcomes'. Together they form a unique fingerprint.

Cite this